France Cancer Immunotherapy Market Size & Outlook
France cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
France cancer immunotherapy market highlights
- The France cancer immunotherapy market generated a revenue of USD 5,715.3 million in 2023 and is expected to reach USD 9,734.3 million by 2030.
- The France market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 5,715.3 million |
| Market revenue in 2030 | USD 9,734.3 million |
| Growth rate | 7.9% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, France accounted for 4.5% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.59% in 2023. Horizon Databook has segmented the France cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Gustave Roussy , one of the first cancer centers in Europe, is a leader in cancer immunotherapy in France as well as Europe. The institute is one of the pioneers in cancer immunotherapeutic research, especially antibodies against CTLA-4, PD-1, and PD-L1.
Furthermore, cancer immunotherapy is one of the top priorities at the Institut Curie, which houses the only oncological immunotherapy centerin France Le Centre d'immunothérapie des cancers de l Institut Curie.
Cancer research in France is further supported by several oncology and immunotherapy conclaves and conferences that include discussion on the latest trends in the market. For instance, Fifth International Cancer lmmunotherapy Conference was held in Paris in September 2019.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France cancer immunotherapy market size, by product, 2018-2030 (US$M)
France Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
